Sunday, October 3, 2010

Biomarker for Triple Negative Breast Cancer Found

A breast cancer tested for estrogen receptor (ER), Progesterone receptor (PR) and human epidermal growth factor receptor2 (HER2), if found to be negative is termed as triple negative breast cancer. Although, these triple negative breast cancers are seen in a few cases, there is no clear cut recommendation of adjuvent therapy. Also, these are more aggressive in nature.

Recently, scientists are categorizing breast cancer on the receptor status and chalking out strategic planning of treatment. Though some medications used in receptor positive cancers have effect on triple negative cancer, still those are not fully responsive.
To find more targeted approach scientists are focusing on it. Now, they have found out that insulin like growth factor receptor (IGF-1R) over expression is associated with less outside spread of breast cancer, i.e. the more is this protein the better is the outcome for triple negative breast cancer. Less IGF-1R is associated with more spread to lymph nodes. High expression levels were also linked to longer survival rates among patients younger than 55 years.
The next step forward is perhaps to learn if triple-negative breast cancer patients benefit from targeting IGF-1R.
Enhanced by Zemanta


Get my updates delivered into your inbox; Privacy Policy :

Click here to Subscribe news feed from "Clinicianonnet; so that you do not miss out anything that can be valuable to you !!


Related Posts Plugin for WordPress, Blogger...